New Clinical Studies show Improved Melanoma Detection by US clinicians with Nevisense

Advertisement

BEGIN ARTICLE PREVIEW:

STOCKHOLM, Sept. 16, 2020 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO:SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that both the Journal of the American Academy of Dermatology (JAAD) and SKIN, The Journal of Cutaneous Medicine (SKIN), have published studies assessing the clinical impact of Nevisense. The studies compared the results of US clinicians evaluating atypical pigmented skin lesions (atypical moles) using visual evaluation only compared to visual evaluation and the Nevisense result combined.

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE